- Trial phase
- Phase 1b/2
- Time to market
- If Phase 1b/2 data are positive (expected end of 2027), a Phase 2 or pivotal trial would follow, putting potential approval several years away, likely 2029 or later.
- Why 3/10
- No hard binary catalyst (PDUFA or pivotal readout) is scheduled for nenocorilant in the next ~12 months. Corcept expects Phase 1b dose-finding results from the SYNERGY trial by the end of 2027. The drug is an early-stage (Phase 1b/2) asset at a commercial-stage company with multiple approved products and a major PDUFA for relacorilant on December 17, 2026, which will dominate the stock's near-term moves.
The next catalyst for nenocorilant is Phase 1b dose-finding data from the SYNERGY trial, which Corcept expects by the end of 2027. The stock's near-term binary is the relacorilant PDUFA on December 17, 2026, which will dominate investor attention. Nenocorilant is too early-stage to move the stock independently in the near term.
Price Chart
Executive Summary
Nenocorilant (also known as CORT125236, formerly ORIC-101) is an oral, selective glucocorticoid receptor (GR) antagonist being developed by Corcept Therapeutics (NASDAQ: CORT) for oncology. It is currently in a Phase 1b/2 SYNERGY trial (NCT07276373) combining nenocorilant with Bristol Myers Squibb's nivolumab (Opdivo) in patients with advanced solid tumors. The Phase 1b dose-finding portion is still enrolling, and Corcept expects results by the end of 2027. The drug's predecessor (ORIC-101) showed acceptable safety but limited efficacy in a prior Phase 1b prostate cancer trial. Nenocorilant is an early-stage pipeline asset at a profitable commercial-stage company whose near-term stock value is dominated by the December 17, 2026 PDUFA for relacorilant in Cushing's syndrome.
How It Works
Nenocorilant is a pill that blocks the glucocorticoid receptor (GR), a protein that cortisol and similar hormones activate. In many cancers, GR signaling helps tumors resist chemotherapy and immunotherapy. By blocking GR, nenocorilant aims to make cancer cells more sensitive to treatment. It is being tested in combination with the immunotherapy drug nivolumab (Opdivo) in patients with advanced solid tumors.
Trial Status
The SYNERGY trial (NCT07276373) is a Phase 1b/2 open-label study evaluating nenocorilant plus nivolumab in advanced solid malignancies. The Phase 1b dose-finding portion is actively recruiting (estimated 30 patients). A trial-in-progress poster was presented at ASCO 2026. Corcept expects Phase 1b results by the end of 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 1b dose-finding data from SYNERGY trial expected by end of 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CORCEPT THERAPEUTICS INC 8-K CORT ·Originating report